Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing that Telomir-1 prevented cellular aging in patient-derived cells from children with progeria—Hutchinson-Gilford Progeria Syndrome (HGPS)—an...
MAIA Biotechnology (NYSE American: MAIA) announced it has entered into a master supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to investigate the combination of MAIA’s telomere-targeting agent ateganosine...
Ekso Bionics Holdings (NASDAQ:EKSO) has announced that it has successfully demonstrated initial proof-of-concept in integrating new AI-enabled capabilities across its portfolio of Enterprise Health and Personal Health...
Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing...
BioRestorative Therapies (NASDAQ: BRTX) announced the presentation of promising preliminary blinded data from the first 36 subjects in its ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for...
Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...
Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...
Profound Medical (NASDAQ: PROF; TSX: PRN) announced that the first commercial benign prostatic hyperplasia (BPH) treatment utilizing the TULSA-PRO system’s new TULSA-AI Volume Reduction Module was successfully conducted...
Citius Oncology (NASDAQ: CTOR) announced it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH). According to Citius, the agreement is designed to help provide access to LYMPHIR, an...
Leef Brands (CSE: LEEF; OTCQB: LEEEF) announced it has officially closed on the acquisition of a Type 1 Cannabis Processor License in New York, enabling the company to engage in extraction, blending, infusion...